emmonsiosis

Also Known As:

Emergomyces africanus infection; Emergomycosis; Emmonsia helica infection; Emmonsia pasteurian infection; chrysosporium infection

Networked: 6 relevant articles (0 outcomes, 0 trials/studies)

Disease Context: Research Results

Infections: 526564
- Bacterial Infections and Mycoses: 1
  - Mycoses: 11300
    - emmonsiosis: 6

Related Diseases

1.	Thrombocytopenia (Thrombopenia)
2.	Infections
3.	Diabetes Mellitus

Experts

1.	Govender, Nelesh P: 3 articles (07/2021 - 01/2017)
2.	Maphanga, Tsidiso G: 3 articles (07/2021 - 01/2017)
3.	Schwartz, Ilan S: 3 articles (07/2021 - 01/2017)
4.	Mpembe, Ruth S: 2 articles (07/2021 - 01/2017)
5.	Naicker, Serisha D: 2 articles (07/2021 - 01/2017)
6.	Bamford, Colleen: 1 article (07/2021)
7.	Gómez, Beatriz L: 1 article (07/2021)
8.	Mhlanga, Mabatho: 1 article (07/2021)
9.	Nel, Jeremy: 1 article (07/2021)
10.	Crombie, Kenneth: 1 article (01/2018)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to emmonsiosis:

1.	Itraconazole (Sporanox)FDA LinkGeneric 01/01/2018 - "Paradoxical worsening of Emergomyces africanus infection in an HIV-infected male on itraconazole and antiretroviral therapy." 01/01/2017 - "In vitro susceptibility data support the management of disseminated emmonsiosis with amphotericin B, followed by itraconazole, voriconazole, or posaconazole. "
2.	Voriconazole (Vfend)FDA LinkGeneric 01/01/2017 - "In vitro susceptibility data support the management of disseminated emmonsiosis with amphotericin B, followed by itraconazole, voriconazole, or posaconazole. "
3.	EnzymesIBA 07/06/2021 - "Cross-reactivity of a Histoplasma capsulatum antigen enzyme immunoassay in urine specimens from persons with emergomycosis in South Africa."
4.	AntigensIBA 07/06/2021 - "Cross-reactivity of a Histoplasma capsulatum antigen enzyme immunoassay in urine specimens from persons with emergomycosis in South Africa."
5.	Amphotericin B (Amphotericin)FDA LinkGeneric 01/01/2017 - "In vitro susceptibility data support the management of disseminated emmonsiosis with amphotericin B, followed by itraconazole, voriconazole, or posaconazole. "
6.	posaconazole FDA Link 01/01/2017 - "In vitro susceptibility data support the management of disseminated emmonsiosis with amphotericin B, followed by itraconazole, voriconazole, or posaconazole. "
7.	N 30IBA 10/23/2023 - "The underlying disease and risk factors significantly associated with emergomycosis in the HIV-infected patients were CD4+ T-cell counts less than 100 cells/mm3 (n = 55, 90.2%), anaemia (n = 30, 49.2%), and thrombocytopenia (n = 17, 27.9%), whereas in the HIV-uninfected patients, treatment with immunosuppressive drugs (n = 10, 62.5%), renal disease (n = 8, 50%), transplant recipients (n = 6, 37.5%), and diabetes mellitus (n = 4, 25%) were the significant risk factors associated with emergomycosis. "

Therapies and Procedures

1.	Therapeutics 03/01/2023 - "Purpose of Review In this review, we provide an overview of emergomycosis from a clinical perspective and discuss the taxonomy and classification of the pathogens, epidemiology, pathophysiology of infection and mechanisms of pathogenesis, immunology, clinical manifestations, laboratory culture and diagnosis, molecular characterisation, therapy and prognosis. " 01/01/2018 - "Paradoxical worsening of Emergomyces africanus infection in an HIV-infected male on itraconazole and antiretroviral therapy."
2.	Body Piercing (Piercing, Body) 05/01/2015 - "We herein report a case of primary cutaneous Chrysosporium infection following ear piercing in an immunocompetent patient. " 05/01/2015 - "Primary Cutaneous Chrysosporium Infection following Ear Piercing: A Case Report."